Search

Can intravitreal anti-VEGF injections affect corneal nerves?

This was a retrospective case-control study looking at the effect of anti-VEGF injections on corneal nerves (CN). Fifty-seven patients with a history of at least three anti-VEGF injections in one or both eyes and available confocal microscopic imaging were included...

Licence to save: a UK survey of anti-VEGF use for the eye

This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...

Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents

In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...

Comparison of retinal pigment epithelium-choroid graft surgery and anti-VEGF therapy in patients with wet AMD

This was a randomised intervention study in wet AMD patients to investigate benefits of free RPE-choroid graft transplantation surgery versus (continuation of) anti-VEGF treatment. Twenty patients who met the inclusion criteria were subdivided into three subgroups, i.e. RPE tears involving...

CD73 in aggressive basal cell carcinoma

This is a retrospective review looking at levels of CD73 in aggressive basal cell carcinomas (BCCs) that invade the orbit. Eleven patients who underwent orbital exenteration for invasion by BCCs were compared with 10 matched controls who had simple nodular...

Rituximab as an immunosuppression treatment for thyroid eye disease

Thyroid eye disease is traditionally treated with high dose glucocorticosteroids and surgical orbital decompression, where responses are often inadequate. This medical treatment is centred around symptom control and reduction of thyroid hormone synthesis, not immunosuppression. Rituximab is an anti-CD20 monoclonal...

Inhibiting high-risk corneal allografts

The cornea is an immune privileged site and as such corneal transplants are very successful. However, in situations where this privilege is lost the failure rises substantially. To combat rejection inhibition of the immune responses depends on steroids and other...